JP2011517654A5 - - Google Patents

Download PDF

Info

Publication number
JP2011517654A5
JP2011517654A5 JP2010524829A JP2010524829A JP2011517654A5 JP 2011517654 A5 JP2011517654 A5 JP 2011517654A5 JP 2010524829 A JP2010524829 A JP 2010524829A JP 2010524829 A JP2010524829 A JP 2010524829A JP 2011517654 A5 JP2011517654 A5 JP 2011517654A5
Authority
JP
Japan
Prior art keywords
patent document
pat
application publication
patent application
document
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524829A
Other languages
English (en)
Japanese (ja)
Other versions
JP5730572B2 (ja
JP2011517654A (ja
Filing date
Publication date
Priority claimed from US11/900,851 external-priority patent/US20080069891A1/en
Priority claimed from US12/075,543 external-priority patent/US8445018B2/en
Application filed filed Critical
Priority claimed from PCT/US2008/003598 external-priority patent/WO2009035474A1/en
Publication of JP2011517654A publication Critical patent/JP2011517654A/ja
Publication of JP2011517654A5 publication Critical patent/JP2011517654A5/ja
Application granted granted Critical
Publication of JP5730572B2 publication Critical patent/JP5730572B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524829A 2007-09-13 2008-03-19 濫用抵抗性製剤 Active JP5730572B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11/900,851 US20080069891A1 (en) 2006-09-15 2007-09-13 Abuse resistant drug formulation
US11/900,851 2007-09-13
USPCT/US2007/020041 2007-09-14
PCT/US2007/020041 WO2008033523A1 (en) 2006-09-15 2007-09-14 Abuse resistant drug formulation
US12/075,543 US8445018B2 (en) 2006-09-15 2008-03-12 Abuse resistant drug formulation
US12/075,543 2008-03-12
PCT/US2008/003598 WO2009035474A1 (en) 2007-09-13 2008-03-19 Abuse resistant drug formulation

Publications (3)

Publication Number Publication Date
JP2011517654A JP2011517654A (ja) 2011-06-16
JP2011517654A5 true JP2011517654A5 (enExample) 2012-06-07
JP5730572B2 JP5730572B2 (ja) 2015-06-10

Family

ID=39493594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524829A Active JP5730572B2 (ja) 2007-09-13 2008-03-19 濫用抵抗性製剤

Country Status (9)

Country Link
EP (1) EP2200593B1 (enExample)
JP (1) JP5730572B2 (enExample)
CA (1) CA2699142C (enExample)
DK (1) DK2200593T5 (enExample)
ES (1) ES2611794T3 (enExample)
HU (1) HUE032012T2 (enExample)
MX (1) MX336861B (enExample)
PL (1) PL2200593T3 (enExample)
WO (1) WO2009035474A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
WO2009135680A1 (en) 2008-05-09 2009-11-12 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
PL2997965T3 (pl) 2009-07-22 2019-06-28 Grünenthal GmbH Odporna na manipulacje postać dawkowania opioidów wrażliwych na utlenianie
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
WO2011084593A2 (en) * 2009-12-17 2011-07-14 Cima Labs Inc. Abuse-resistant formulations
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
CA2790108C (en) * 2010-02-24 2016-05-31 Cima Labs Inc. Abuse-resistant formulations
EP2568969A2 (en) * 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant formulations
EP2579857A1 (en) * 2010-05-11 2013-04-17 Cima Labs Inc. Alcohol-resistant extended release dosage forms comprising venlafaxine
EP2568977A1 (en) * 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
ES2487244T3 (es) 2010-09-02 2014-08-20 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende un polímero aniónico
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
HRP20181716T1 (hr) 2012-04-18 2018-12-28 Grünenthal GmbH Farmaceutski oblik doziranja otporan na zlonamjernu uporabu i naglo oslobađanje cjelokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
DE102024107711A1 (de) * 2024-03-18 2025-09-18 Glatt Gesellschaft Mit Beschränkter Haftung Vorläufermaterial und Verwendung eines Vorläufermaterials zur Herstellung von Tabletten

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234957A (en) 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US6238704B1 (en) * 1996-09-13 2001-05-29 Shionogi & Co., Ltd. Sustained-release preparation utilizing thermal change and process for the production thereof
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
EP1551402A4 (en) * 2002-09-23 2009-05-27 Verion Inc PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
CN100500130C (zh) * 2003-01-23 2009-06-17 株式会社太平洋 缓释制剂及其制备方法
CA2519556C (en) * 2003-04-21 2011-01-18 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20060263429A1 (en) * 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof

Similar Documents

Publication Publication Date Title
JP2011517654A5 (enExample)
Hua Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration
Tripathi Essentials of medical pharmacology
RU2408368C2 (ru) Препараты соли бупропиона с модифицированным высвобождением
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
CN110290781A (zh) 胃肠特定部位控制释放的剂型
TWI282286B (en) Pharmaceutical composition a bilayer tablet having an immediate release phase of paracetamol and a sustained release phase of paracetamol
TW201106990A (en) Tamper-resistant dosage form for oxidation-sensitive opioids
CA2954637A1 (en) Co-packaged drug products
Webster Update on abuse-resistant and abuse-deterrent approaches to opioid formulations
JP2016185995A5 (enExample)
Gijare et al. Orodispersible films: a systematic patent review
US20170296532A1 (en) Compositions for control of drug abuse
Dhillon Hydrocodone bitartrate ER (Hysingla® ER): a review in chronic pain
Damodar et al. Role of Novel Hole Technology in Fast Dissolving Tablets
JP2013510841A5 (enExample)
JPH07242536A (ja) 皮膜に精油成分が含有されたゼラチンカプセル剤
Dhiman et al. Buccal bioadhesive delivery system of 5-fluorouracil: optimization and characterization
Chwieduk et al. Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer
Gosavi et al. Mouth dissolving films: A review
Reddy et al. Rapidly disintegrating oramucosal drug delivery technologies
WO2023205619A1 (en) Processes for preparation of 3-d printed pharmaceutical products
RS64807B1 (sr) Kombinovani lek koji obuhvata fenilefrin i paracetamol
JP2012031164A (ja) フィルム状製剤
Patil et al. Preparation and Optimization of Fast Dissolving HPMC/PVA Blended films of Loperamide Hydrochloride.